Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Real-world Study of the Efficacy and Safety of Amlotinib for the Treatment of HER2-negative Advanced Breast Cancer

NCT06340165 is registered in ClinicalTrials.gov with The First Hospital of Jilin University as lead sponsor.

NCT NCT06340165
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06340165 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Real-world Study of the Efficacy and Safety of Amlotinib for the Treatment of HER2-negative Advanced Breast Cancer
Lead sponsor
The First Hospital of Jilin University
Phase
Observational
Overall status
Unknown status
Start date
February 4, 2024
Completion date
June 30, 2025
Enrollment
153 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer